Search the MBS

Related Items: 73338

• Previous - Note PN.0.25
• Next - Note PN.0.27

A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if:

(a) requirements relating to rat sarcoma oncogene (RAS) gene variant status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme are fulfilled, if:

1. the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or
2. a clinically-relevant RAS variant is detected;

and, in cases where no RAS variant is detected

(b) the requirements relating to BRAF V600 gene variant status for access to encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.

Fee: $362.60 Benefit: 75% = $271.95 85% = $308.25

(See para PN.0.26 of explanatory notes to this Category)

• Previous - Item 73337
• Next - Item 73339